Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Entegris Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while Entegris Inc trades at $166.06 (market cap $25.41B). The key difference: Entegris Inc is far larger — about 5.4× Definium Therapeutics Inc. Common Shares's market cap, and Entegris Inc pays a 0.24% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Entegris Inc for 41 Days on average.
| DFTX | ENTG | |
|---|---|---|
Market Cap | $4.71B | $25.41B |
Volume | 1,966,636 | 2,160,232 |
Sector | Health | Technology |
52-Week High | $48.45 | $184.00 |
52-Week Low | $10.68 | $68.80 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $3.67B | $28.62B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ENTG trades at $162.19, down 2.82% today, with strong technical momentum as moving averages signal bullish alignment. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $0.93 versus $0.82, driven by AI-related semiconductor demand. Revenue remains stable at $3.2B in 2025, while net income margin improved to 9.18% in 2026 projections. Recent institutional buying includes BlackRock's $3.68 billion position, reflecting confidence in Entegris' advanced materials leadership.
Outlook remains positive with analyst consensus target of $182.43 suggesting 12.5% upside, supported by 70% buy ratings. Key risks include high valuation multiples (P/E 83.16) and semiconductor cycle sensitivity. The upcoming Q3 earnings on October 29, 2026, and Investor Day on November 9, 2026, are critical catalysts for confirming growth trajectory amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
